Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis

Gupta, Shiva; Solomon, Jeffrey; Tasciyan, Talin A.; Cao, Mengqiu; Stone, Roger D.; Ostuni, John; Ohayon, Joan; Muraro, Paolo A.; Frank, Joseph A.; Richert, Nancy; McFarland, H. F.; Bagnato, Francesca

doi:10.1191/1352458505ms1229oa

Cited by 13 publications

(21 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More specifically, CELs lasting longer and potentially being larger were included, thus introducing some comparability issues with our results. In this regard, the results from Di Rezze and colleagues parallel the ones reported by Gupta and colleagues on the subset of larger and longer lasting CELs, for which an effect of IFN in reducing the lesions' size is observed instead [21]. Second, Di Rezze and colleagues took only single measurements of CELs into account, which is the one corresponding to the available MRI.…”

Section: Discussionmentioning

confidence: 56%

“…We recognize that our results are limited only to CELs lasting up to 2 months. However, it is well known that, as seen in our study cohort, those CELs represent the majority of active CELs in patients with MS [6,17,21,29]. Moreover, although restricted by those limitations, the analysis preserved some comparability between those lesions detected during the pre and therapy phases.…”

Section: Discussionmentioning

confidence: 81%

“…Details of the adopted MRI protocol have been described previously [21]. Contrast-enhanced images were collected within 15 min after gadolinium dimegumine (Gd) (Magnevist, Berlex Labs.…”

Section: Methodsmentioning

confidence: 99%

“…Details of the methodology are described elsewhere [21]. Briefly, the linear registration tool FLIRT 3.1 [28] was used to register each patient's monthly MRIs onto the first pre-therapy phase MRI.…”

Section: Methodsmentioning

confidence: 99%

“…However, the specific question as to whether IFN-β reduced CELs size once formed or persisting during the therapy phase has rarely been investigated. In previous work by our group, it was shown that IFN-β-1b effectively reduced the maximum lesion size of larger lesions enhancing multiple times over the course of several monthly observations, rather than short-lived lesions enhancing only once [21]. Although potential biases due to outlier cases were considered and corrected in this work, the results suffered from the small number of patients examined and warranted investigation in larger study cohorts.…”

Section: Introductionmentioning

confidence: 95%

See 4 more Smart Citations

The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis

Gaindh¹,

Jeffries²,

Ohayon³

et al. 2008

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Background Contrast enhancing lesions (CELs) in MRI represent inflammatory events in multiple sclerosis (MS). IFN-β-1b decreases the formation of CELs. However, the ability of IFN-β-1b to reduce the size of CELs arising during therapy has not been extensively investigated. Methods Thirty patients with relapsing-remitting (RR) MS were followed for a 3-month pre-therapy phase then for a 6-month therapy phase during which treatment with IFN-β-1b at a dosage of 250 μg subcutaneously injected every other day was employed. Each patient underwent monthly clinical and MRI examinations. For all patients, CELs were identified on postcontrast T1-weighted MRIs. CEL number, size, and volume were computed using Medx software. Results The average number and total lesion volume of CELs visible during the therapy phase were significantly lower than the number and total lesion volume of CELs observed in the pre-therapy phase. However, there was no significant reduction between pre-therapy and therapy phases in the mean size of individual lesions arising during the respective phases. Conclusions Since size of CELs has been related to severity of tissue damage, the lack of size decrease during therapy suggested a limited therapeutic effect of IFN-β-1b if a blood–brain barrier breakdown has occurred.

show abstract

Section: Discussionmentioning

confidence: 56%

Section: Discussionmentioning

confidence: 81%

“…Details of the adopted MRI protocol have been described previously [21]. Contrast-enhanced images were collected within 15 min after gadolinium dimegumine (Gd) (Magnevist, Berlex Labs.…”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 95%

See 3 more Smart Citations

The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis

Gaindh¹,

Jeffries²,

Ohayon³

et al. 2008

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

Imaging chronic active lesions in multiple sclerosis: a consensus statement

Bagnato,

Sati,

Hemond

et al. 2024

Brain

View full text Add to dashboard Cite

Chronic active lesions (CAL) are an important manifestation of chronic inflammation in multiple sclerosis (MS) and have implications for non-relapsing biological progression. In recent years, the discovery of innovative magnetic resonance imaging (MRI) and PET derived biomarkers has made it possible to detect CAL, and to some extent quantify them, in the brain of persons with MS, in vivo. Paramagnetic rim lesions on susceptibility-sensitive MRI sequences, MRI-defined slowly expanding lesions on T1-weighted (T1-w) and T2-w scans, and 18-kDa translocator protein-positive lesions on PET are promising candidate biomarkers of CAL. While partially overlapping, these biomarkers do not have equivalent sensitivity and specificity to histopathological CAL. Standardization in the use of available imaging measures for CAL identification, quantification, and monitoring is lacking. To fast-forward clinical translation of CAL, the North American Imaging in Multiple Sclerosis Cooperative developed a Consensus Statement, which provides guidance for the radiological definition and measurement of CAL. The proposed manuscript presents this Consensus Statement, summarizes the multistep process leading to it, and identifies the remaining major gaps in knowledge.

show abstract

Diffuse and Focal Corticospinal Tract Disease and Its Impact on Patient Disability in Multiple Sclerosis

Tovar‐Moll

Evangelou

Chiu

et al. 2014

Journal of Neuroimaging

View full text Add to dashboard Cite

Background and Purpose We investigated the impact of focal and diffuse corticospinal tracts damage on sensory-motor disability in multiple sclerosis (MS) patients. Methods Twenty-five MS patients underwent 3.0 Tesla (3T) magnetic resonance imaging with diffusion tensor imaging (DTI). The Expanded Disability Status Scale (EDSS) and the Timed 25-Foot Walk test (T25FW) quantified patient physical disability. Fractional anisotropy (FA) and mean diffusivity (MD) of the corticospinal tracts, whole brain and corticospinal tracts lesion volume were also computed. Spearman rank correlation analyses measured the associations between DTI-derived metrics and other measures of disease. Partial correlation analyses between DTI and disability measures were performed and corrected for lesion volumes as appropriate. Results Significant associations were seen between FA of the corticospinal tracts and EDSS (r =−0.500, p =0.0011), motor-EDSS (r = −0.519, p=0.008), and T25WF (r=−0.637, p =0.001) scores and MD of the corticospinal tracts and motor-EDSS (r=0.469, p=0.018) and T25WF (r=0.428, p=0.033) scores. When correcting for lesion volumes, only the association between FA of the corticospinal tracts and EDSS (p≤0.01, r≤ −0.516) or motor-EDSS score (p=0.03, r=−0.468,) persisted. Conclusions DTI at 3T shows that the impact of diffuse corticospinal tracts disease on sensory-motor disability is greatly mediated by focal lesions in MS.

show abstract

Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis

Cited by 13 publications

References 31 publications

The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis

The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis

Imaging chronic active lesions in multiple sclerosis: a consensus statement

Diffuse and Focal Corticospinal Tract Disease and Its Impact on Patient Disability in Multiple Sclerosis

Contact Info

Product

Resources

About